A DNA TRANSFER VECTOR FOR HUMAN PRE-GROWTH HORMONE, A MICROORGANISM TRANSFORMED THEREBY, AND A METHOD OF CLONING THEREFOR

Abstract: A DNA having a base sequence coding for human pregrowth hormone has been cloned, and novel recombinant DNA transfer vectors containing said cloned DNA have been constructed. Novel microorganisms transformed by said recombinant transfer vectors have been obtained. Certain of said transformed microorganisms have demonstrated capability to express the cloned DNA, by synthesizing a protein comprising human pre-growth hormone.

Description: A DNA transfer vector for human pre-growth hormone, a microorganism transformed thereby, and a method. of cloning therefor. The invention relates t a DNA transfer vector comprising a deoxynucleotide sequence coding for human pre-growth hormone. It also relates to a microorganism transformed thereby, and to a method of cloning therefor. The invention herein provides the isolated and purified (hereinafter "cloned") human gene coding for growth hormone, including a portion of the pre-sequence thereof, a method for isolating and purifying the gene, and a method for transferring the gene to and replicating the gene in a microorganism. The cloned gene is expressed by a host microorganism when fused with a host-expressible procaryotic gene. The gene is useful in the production of human growth hormone for therapeutic purposes. Growth hormone is produced principally by the anterior lobe of the pituitary gland, also termed the adenohypophysis. The hormone is normally produced throughout life, although in highest amounts during. childhood. Although its mechanism of action is not understood in detail, growth hormone is known to affect glucose and lipid metabolism and to promote protein synthesis. A variety of clinical disorders attributable to growth hormone deficiency are known. Severe cases of pituitary dwarfism are currently treated with human growth hormone isolated from cadavers. Since most non-primate growth hormones are ineffective in humans, there is no suitable alternative source. The supply of material is very small, the procedure for isolating and purifying the hormone is complex and expensive. This is illustrated by the fact that the cost of treatment is estimated in the U.S.A. to be $5000.00 per year per patient. Currently, treatment of growth hormone deficiency is limited to the most severe cases. More than 1000 new patients require treatment each year. If an adequate supply of hormone were available at reasonable cost, many thousands of patients with less severe deficiency conditions or with certain other growth problems would be treatable. In addition, experimental evidence indicates that human growth hormone is useful for treatment of gastrointestinal haemorrhage, fracture healing, metabolic bone disease and wound healing. Growth hormone is a protein. The amino acid sequence of human growth hormone, determined by conventional techniques, is given in Table 1. 1 TABLE 1 10 NH2-Phe-Pro-Thr-Ile-Pro-Leu-Ser-Arg-Leu-Phe-Asp-Asn-Ala-Met 20 Leu-Arg-Ala-His-Arg-Le8-His-Gln-Leu-Ala-Phe-Asp-Thr-Tyr- Glu-G08-Phe-Glu-Glu-Ala-Tyr-Ile-Pro-Lys-Glu-Gin-Lys-Tyr- Ser-Phe-Leu-Gln-Asn-Pro-Gln-TRr-Ser-Leu-Cys-Phe-Ser-Glu Ser-Ile-Pro-T500-Pro-Ser-Asn-Arg-Glu-Glu-Thr-Gln-Gln-LysO- Ser-Asn-Leu-Gln-Leu-Leu-Arg-Ile-Ser-Le8-Leu-Leu-Ile-Gln- Ser-Try-Leu-Clu-Pro-Va99-Clu-Phe-Leu-Arg-Ser-Val-Phe-Ala- Asn-Aer-Leu-Val-Tyr-Gly-Ala-ser-Asn-ser-Asp-q!a-Tyr-Asp- Leu-Leu-Lys-Asp-Leu-Glu-Glu- & y-Ile-Gln-Thr-Leu-Met-Gly- Arg-Leu-Glu-Asp0-Gly-Ser-Pro-Arg-Thr-Gly-Gln-Ile-Phe-L40s- Gln-Thr-Tyr-Ser-Lys-Phe-Asp-Thr-Asn-er-His-Asn-Asp-Asp Ala-Leu-Leu-Lys-Asn- 1y6r0-Cly-Leu-Leu-Tyr-Cys-Phe-Arg-Lys- Asp-0le-Asp-Lys-Val-Glu-Thr-Phe-Leu-Arg-IIe-ba-Gln-Oys- Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-phe-COOH. Chemical synthesis of this sequence of 191 amino acids is not feasible using conventional techniques. In the pituitary gland, the initial biosynthetic product is termed pre-growth hormone and contains, in addition to the sequence of Table 1, a twenty--six aminoacid sequence, termed the signal peptide, attached to the amino-terminal end. The signal peptide sequence is: NH2-Met-Ala-Thr-Gly-Ser-Arg-Thr Ser-Leu-Leu-Leu- la-Phe-Gly-Leu-Leu-Cys-Leu-Pro-Trp-Leu-Gln Glu-Ala-Val-Pro. the twenty-six amino acid signal peptide is considered to function by conferring the ability to insert and pass through the cell membrane, thereby permitting excretion of the protein from the cell in which it was synthesized (See, Blobel, G.-et al., J. Cell. Biol. 67, 835 (1975).) Several instances of signal peptides are known for eucaryotic proteins to be transported across membrane barriers. A specific cleavage enzyme has been observed in a cell-free system which hydrolyzes the peptide bond between the signal peptide and the active protein in association with passage through a cell membrane. (See, Blobel, G. et al., Proc. Nat. Acad. Sci; USA -75, 361 (1978). Recent advances in biochemistry and in recombinant DNA technology have made it possible to achieve the synthesis of specific proteins under controlled conditions independent of the higher organism from which they are normally isolated. Such biochemical synthetic methods employ enzymes and subcellular components of the protein synthesizing machinery of living cells, either in vitro, in cell-free systems, or in vivo, in microorganisms. In either case, the key element is provision of a deoxyribonucleic acid (DNA) of specific sequence which contains the information necessary to specify the desired amino acid sequence. Such a specific DNA is herein termed a gene. The coding relationship whereby a deoxynucleotide sequence is used to specify the amino acid sequence of a protein is described briefly, infra, and operates according to a fundamental set of principles that obtain throughout the whole of the known realm of living organisms. A cloned gene may be used to specify the amino acid sequence of proteins synthesized by in vitro systems. DNAdirected protein synthesizing systems are well-known in the art, see, e.g., Zubay, G., Ann.Rev.Genetics 7, 267 (1973). In addition, single-stranded DNA can be induced to act as messenger RNA in vitro, resulting in high fidelity translation of the DNA sequence (Salas, J. et al., J. Biol. Chem. 243, 1012 (1968). Other techniques well known in the art may be used in combination with the above procedures to enhance yields. Developments in recombinant DNA technology have made it possible to isolate specific genes or portions thereof from higher organisms, such as man and other mammals, and to transfer the genes or fragments to a microorganism, such as bacteria or yeast. The transferred gene is replicated and propagated as the transformed microorganism replicates. As a result, the transformed microorganism may become endowed with the capacity to make whatever protein the gene or fragment encodes, whether it be an enzyme, a hormone, an antigen or an antibody, or a portion thereof. The microorganism passes on this capability to its progeny, so that in effect, the transfer has resulted in a new strain, having the described capability. See, for example, Ullrich, A. et al., Science 196, 1313 (1977), and Seeburg, PH. et al, Nature 270, 486 (1977). A basic fact underlying the application of this technology for practical purposes is that DNA of all living organisms, from microbes to man, is chemically similar, being composed of the same four nucleotides. The significant differences lie in the sequences of these nucleotides in the polymeric DNA molecule. The nucleotide sequences are used to specify the amino acid sequences of proteins that comprise the organism. Although most of the proteins of different organisms differ from each other, the coding relationship between nucleotide sequence and amino acid sequence is fundamentally the same for all organisms. For example, the same nucleotide sequence which codes for the amino acid sequence of HGH in human pituitary cells, will, when transferred to a microorganism, be recognised as coding for the same amino acid sequence. Abbreviations used herein are given in Table 2. TABLE 2 DNA - deoxyribonucleic acid A - Adenine RNA - ribonucleic acid T - Thymine cDNA - complementary DNA G - Guanine (enzymatically synthesized C - Cytosine from an mRNA sequence) U - Uracil mRNA - messenger RNA ATP - adenosine triphosphate dATP - deoxyadenosine triphosphate TTP - thymidine triphosphate dCTP - deoxyguanosine triphosphate EDTA - Ethylenediamine tetra-acetic acid dCTP - deoxycytidine triphosphate The coding relationships between nucleotide sequence in DNA and amino acid sequence in protein are collectively known as the genetic code, shown in Table 3. TABLE 3 Genetic Code Phenylalanine (Phe) TTK Histidine (His) CAK Leucine (Leu) XTY Glutamine (Gln) CAJ Isoleucine (Ile) ATM Asparagine (Asn) AAK Methionine (Met) ATG Lysine (Lys) AAJ Valine (Val) GTL Aspartic acid (Asp) GAK Serine (Ser) QRS Glutamic acid (Glu) GAJ Proline (Pro) CCL Cysteine (Cys) TGK Threonine (Thr) ACL Tryptophan (Try) TGG Alanine (Ala) GCL Arginine (Arg) WCZ Tyrosine (Tyr) TAK Glycine (Gly) GGL Termination signal TAJ Termination signal TGA Key: Each 3-letter deoxynucleotide triplet corresponds to a trinucleotide of mRNA, having a 5'-end on the left and a 3'-end on the right. All DNA sequences given herein are those of the strand whose sequence corresponds to the mRNA sequence, with thymine substituted for uracil. The letters stand for the purine or pyrimidine bases forming the deoxynucleotide sequence. A = adenine J = A or G G = guanine K = T or C C = cytosine L = A, T, C or G T = thymine M = A, C or T X = T or C if Y is A or G X = C if Y is C or T Y = A, G, C or T if X is C Y = A or G if X is T W = C or A if Z is A or G W = C if Z is C or T Z = A, G, C or T if W is C Z = A or G if W is A QR = TC if S is A, G, C or T QR = AG if S is T or C S = A, G, C or T if QR is TC S = T or C if QR is AG An important feature of the code, for present purposes, is the fact that each amino acid is specified by a trinucleotide sequence, also known as a nucleotide triplet. The phosphodiester bonds joining adjacent triplets are chemically indistinguishable from all other internucleotide bonds in DNA. Therefore the nucleotide sequence cannot be read to code for a unique amino acid sequence without additional information to determine the reading frame, which is the term used to denote the grouping of triplets used by the cell in decoding the genetic message. Many recombinant DNA techniques employ two classes of compounds, transfer vectors and restriction enzymes, to be discussed in turn. A transfer vector is a DNA molecule which contains, inter alia, genetic information which insures its own replication when transferred to a host microorganism strain. Examples of transfer vectors commonly used in bacterial genetics are plasmids and the DNA of certain bacteriophages. Although plasmids have been used as the transfer vectors for the work described herein, it will be understood that other types of transfer vectors may be employed. Plasmid is the term applied to any autonomously replicating DNA unit which might be found in a microbial cell, other than the genome of the host cell itself. A plasmid is not genetically linked to the chromosome of the host cell. Plasmid DNA's exist as double-stranded ring structures generally on the order of a few million daltons molecular weight, although some are greater than 10 daltons in molecular weight. They usually represent only a mall percent of the total DNA of the cell. Transfer vector DNA is usually separable from host cell DNA by virtue of the great difference in size between them. Transfer vectors carry genetic information enabling them to replicate within the host cell, in most cases independently of the rate of host cell division. Some plasmids have the property that their replication rate can be controlled by the investigator by variations in the growth conditions. Plasmid DN exists as a closed ring. However, by appropriate techniques, the ring may be opened, a fragment of heterologous DNA inserted, and the ring reclosed, forming an enlarged molecule comprising the inserted DNA segment. Bacteriophage DNA may carry a segment of heterologous DNA inserted in place of certain non-essential phage genes. Either way, the transfer vector serves as a carrier or vector for an inserted fragment of heterologous DNA. Transfer is accomplished by a process known as transformation. During transformation, bacterial cells mixed with plasmid DNA incorporate entire plasmid molecules into the cells. Although the mechanics of the process remain obscure, it is possible to maximize the proportion of -bacterial cells capable of taking up plasmid DNA and hence of being transformed, by certain empirically determined treatments. Once a cell has incorporated a plasmid, the latter is replicated within the cell and the plasmid replicas are distributed to the daughter cells when the cell divides. Any genetic information contained in the nucleotide sequence of the plasmid DNA can, in principle, be expressed in the host cell. Typically, a transformed host cell is recognised by its acquisition of traits carried on the plasmid, such as resistance to certain antibiotics. Different plasmids are recognisable by the different capabilities or combination of capabilities which they confer upon the host cell containing them. Any given plasmid may be made in quantity by growing a pure culture of cells containing the plasmid and isolating the plasmid DNA therefrom. Restriction endonucleases are hydrolytic enzymes capable of catalyzing site-specific cleavage of DNA molecules. The locus of :restriction endonuclease action is determined by the existence of a specific nucleotide sequence. Such a sequence is termed the recognition site for the restriction endonuclease. Restriction endonucleases from a variety of sources have been isolated anefieraeactsr- ized in terms of the nucleotide sequence of their recognition sites. Some restriction endonucleases hydrolyze the phosphodiester bonds on both strands at the same point, producing blunt ends. Others catalyze hydrolysis of bonds separated by a few nucleotides from each other, producing free single stranded regions at each end of the cleaved molecule. Such single stranded ends are self-c-omplementary, hence cohesive, and may be used to rejoin the hydrolyzed DNA. Since any DNA susceptible of cleavage by such an enzyme must contain the same recognition site, the same cohesive ends will be produced, so that it is possible to join heterologous sequences of DNA which have been treated with restriction endonuclease to other sequences similarly treated. See Roberts, R.J., Crit. Rev. Biochem. 4, 123 (1976). Restriction sites are relatively rare, however the general utility of restriction endonucleases has been greatly amplified by the chemical synthesis of double stranded oligonucleotides bearing the restriction site sequence. Therefore virtually any segment of DNA can be coupled to any other segment simply by attaching the appropriate restriction oligonucleotide to the ends of the molecule, and subjecting the product to the hydrolysis action of the appropriate restriction endonuclease, thereby producing the requisite cohesive ends. See Heyneker, H.L., et al, Nature 263,748 21976) and Scheller, R.H. , et al, Science 196, 177 (1977). An important feature of the distribution of restriction endonuclease recognition sites is the fact that they are randomly distributed with respect to reading frame. Consequently, cleavage by restriction endonuclease may occur between adjacent codons or it may occur within a codon. More general methods for DNA cleavage or for end sequence modification are available. A variety of nonspecific endonucleases may be used to cleave DNA randomly, as discussed infra. End sequences may be modified by creation of oligonucleotide tails of dA on one end and dT at the other, or of dG and dC, to create restriction sites without the need for specific linker sequences, when the ends are joined. The term "expression" is used in recognition of the fact that an organism seldom if ever makes use of all its genetically endowed capabilities at any given time. Even in relatively simple oragnisms such as bacteria, many proteins which the cell is capable of synthesizing are not synthesized, although they may be synthesized under appropriate environmental conditions. When the protein product, coded by a given gene, is synthesized by the organism, the gene is said to be expressed If the protein product is not made, the gene is not expressed. Normally, the expression of genes in E. coli is regulated. as described generally, infra, in such manner that proteins whose function is not useful in a given environment are not synthesized and metabolic energy is conserved The means by which gene expression is controlled in E. coli is well understood, as the result of extensive studies over the past twenty years. See, generally, Hayes, W., The Genetics of Bacteria and Their Viruses, 2d edition, John Wiley & Sons, Inc, New York (1968), and Watson, J.D., The Molecular Biology of the Gene, 3d edition, Benjamin, Menlo Park, California (1976). These studies have revealed that several genes, usually those coding for proteins carrying out related functions in the cell, are found clustered together in continuous sequence. The cluster is called an operon. All genes in the operon are transcribed in the same direction, beginning with the codons coding for the N-terminal amino acid of the first protein in the sequence and continuing through to the C-terminal end of the last protein in the op-eron. At the beginning of the operon, proximal to the N-terminal amino acid codon, there exists a region of tWe-DNA, termed the control region, which includes a variety of controlling elements including the operator, promoter and sequences for the ribosomal binding sites. The function of these sites is to permit the expression of those genes under their control to be responsive to the needs of the organism. For example, those genes coding for enzymes required exclusively for utilization of lactose are normally not appreciably expressed unless lactose or an analog thereof is actually present in the medium. The control region functions that must be present for expression to occur are the initiation of transcription and the initiation of translation. Expression of the first gene in the sequence is initiated by the initiation of transcription and translation at the position coding for the N-terminal amino acid of the first protein of the operon. The expression of each gene downstream from that point is also initiated in turn, at least until a termination signal or another operon is encountered with its own control region, keyed to respond to a different set of environmental cues. While there are many variations in detail on this general scheme, the important fact is that, to be expressed in a procaryote such as E. coli, a gene must be properly located with respect to a control region having initiator of transcription and initiator of translation functions. It has been demonstrated that genes not normally part of a given operon can be inserted within the operon and controlled by it. The classic demonstration was made by Jacob, F., et al, J. Mol. Biol. 13, 704 (1965). In that experiment, genes coding for enzymes involved in a purine biosynthesis pathway were transferred to a region controlled by the lactose operon. The expression of the purine biosynthetic enzyme was then observed to be repressed in the absence of lactose or a lactose analog, and was rendered unresponsive to the environmental cues normally regulating its expression. In addition to the operator region regulating the initiation of transcription of genes downstream from it, there are known to exist codons which function as stop signals, indicating the C-terminal end of a given protein. See Table 2. Such codons are known as termination signals and also as nonsense codons, since they do not normally code for any amino acid. Deletion of a termination signal between structural genes of an operon creates a fused gene which could result in the synthesis of a chimeric protein consisting of two amino acid sequences coded by adjacent genes, joined by a peptide bond. That such chimeric proteins are synthesized when genes are fused was demonstrated by Benzer, S., and Champe, S.P., Proc. Nat. Acad. Sci USA 48, 114 (1962). Once a given gene has been isolated, purified and inserted in a transfer vector, the over-all result of which is termed the cloning of the gene, its availability in substantial quantity is assured. The cloned gene is transferred to a suitable microorganism, wherein the gene replicates as the microorganism proliferates and from which the gene may be reisolated by conventional means. Thus is provided a continuously renewable source of the gene for further manipuiations, modifications and transfers to other vectors or other loci}othin the same vector. Expression is obtained by transferring the cloned gene, in proper orientation and reading frame, into a control region such that read-through from the procaryotic gene results in synthesis of a chimeric protein comprising the amino acid sequence coded by the cloned gene. A variety of specific protein cleavage techniques may be used to cleave the chimeric protein at a desired point so as to release the desired amino acid sequence, which may then be purified by conventional means. Techniques for constructing an expression transfer vector having the cloned gene in proper juxtaposition with a control region are described in Polisky, B., et al, Proc. Nat. Acad. Sci USA 73, 3900 (1976); Itakura, K. et al., Science 198, 1056 (1977); Villa-Komaroff, L., et al., Proc. Nat. Acad. Sci USA 75, 3727 (1978); Mercereau-Puijalon, O., et al, Nature 275, 505 (1978); Chang, A.C.Y, et al, Nature 275, 617 (1978), and in U.S. Application Serial No. 933,035 by Rutter, et al, said application incorporated herein by reference as though set forth in full. In summary, the process whereby a mammalian protein, such. as human pre-growth hormone, is produced with the aid of recombinant DNA technology first requires the cloning of the mammalian gene. Once cloned, the gene may be produced in quantity, further modified by chemical or enzymic means and transferred to an expression plasmid. The cloned gene is also useful for isolating related genes, or, where a fragment is cloned, for isolating the entire gene, by using the cloned gene as a hybridization probe. Further the cloned gene is useful in proving by hybridization, the identity of homology of independent isolates of the same or related genes. Because of the nature of the genetic code, the cloned gene, when translated in the proper reading frame, will direct the production only of the amino acid sequence for which it codes and no other. The cloned gene for human pre-growth hormone is useful in a variety of ways. Transposition to an expression transfer vector will permit the synthesis of pre-growth hormones by a host microorganism transformed with the vector carrying the cloned gene. Growth of the transformed host will result in synthesis of pre-growth hormone as part of a chimeric protein. If the procaryotic portion Qf the chimeric protein is the signal portion of an excreted or otherwise compartmentized host protein, excretion or compartmentization can occur, greatly enhancing the stability and ease of purification of the pre-growth hormone chimera. Additionally, where the procaryotic portion is short, excretion from the procaryotic host will be facilitated by the pre-sequence itself, if the pre-sequence functions in the procayotic host as it does in the eucaryotic cell. The cloned gene is further useful in hybridization techniques for the isolation of genetic material having partial sequence homology. The growth hormone genes of other mammalian species are isolatable in this manner since, despite their lack of physiological crossreactivity, sufficient sequence similarly exists for effective hybridization. The growth hormones of various animal species are useful for agricultural and veterinary purposes. The growth hormone gene of an individual human patient is isolatabie by the hybridization technique, for the purpose of analysis and treatment of a specific growth disorder. The cloned pre-growth hormone gene can be used, in a variety of techniques for the production of pre-growth hormone. Pre-growth hormone itself is useful because it can be converted to growth hormone by known enzymatic and chemical techniques For example, the pre-sequence can be removed by a soluble enzymic preparation as described by Blobel, G. supra, specific for removal of signal peptides. As disclosed herein, a cDNA having a base sequence coding for human pre-growth hormone has been cloned. The structure of the cloned cDNA has been verified by nucleotide sequence analysis. The original source of genetic material is human pituitary tumor tissue obtained by surgery. Preferably, genetic material is isolated from the cells of an individual human, and a special technique is disclosed for cloning the gene from individual human tumors. Messenger RNA was isolated from the cells and partially purified by chromatography and sedimentation. Active fractions were identified by their ability to direct the synthesis of a protein of approximately 200 amino acids in a cell-free protein synthesis system, as judged by gel electrophoresis. DNA complementary to the isolated messenger RNA (cDNA) was synthesized using reverse transcriptase, in two reaction cycles to generate double-stranded cDNA, as described in detail, infra. The heterogeneous, reverse transcriptase double-stranded DNA reaction product was fractionated according to length by gel electrophoresis. DNA migrating in a region corresponding to about 800 base pairs in length was chosen for further study. The major portion of the 800 base-pair cDNA was shown to be that coding for growth hormone by separately treating it with the restriction endonucleases PvuII and II. PvuII is known to cleave growth hormone cDNA to yield an approximately 495 basepair fragment. Bg1II is known to have one cleavage site within this fragment. After cleavage and fractionation the anticipated bands characteristic of growth hormone cDNA were obtained. The uncleaved, heterogeneous, double-stranded cDNA of approximately 800 base pairs length was treated to provide specific linker oligonucleotide sequences at each end, to facilitate insertion into a site of the same restriction specificity on a transfer vector. For cloning, a transfer vector providing good selection and stable replication properties was selected. The treated, 800 base-pair cDNA was inserted into a transfer vector at a predetermined site on the vector DNA to form a recombinant transfer vector, using currently available techniques. Host microorganism cells were transformed with the recombinant vector. Transformants were selected according to the criteria established for insertion at the predetermined site. Single colonies, each derived from a single transformed microorganism cell, were picked and grown in individual cultures to permit replication of the recombinant transfer vector DNA clones. Transfer vector DNA was then isolated and run on slab gel electrophoresis runs used to screen for transfer vectors of the correct size and to eliminate defects, such as deletions. Colonies yielding recombinant transfer vector DNA of appropriate size were grown in larger individual cultures to isolate transfer vector DNA and subject the DNA to restriction enzyme analysis. The DNA inserted in the transfer vector could be identified, for each clone, by treatment with the restriction enzyme used to cleave at the insertion site, and by the enzymes PvuII and B91II, with which growth hormone cDNA yields a characteristically sized fragment. A clone satisfying all requirements was selected for definitive identification of the nucleotide sequence of the cloned pre-growth hormone gene, and for transfer to an appropriate expression plasmid. Growth hormone is synthesized exclusively by the anterior lobe of the pituitary gland in normal individuals. In principle, the gene for growth hormone could be isolated from any tissue. However, there are intervening sequences in the human growth hormone gene which, in the normal eucaryotic environment, are transcribed and then processed out to yield the "mature" mRNA without intervening sequences. A deoxynucleotide sequence translatable in a procaryotic cell, such as a bacterium may not contain such intervening sequences, since procaryotic cells would be expected to translate such sequences giving rise to an undesired protein product. There, as a practical matter, the deoxynucleotide sequence must be derived from messenger RNA isolated from cells actively synthesing growth hormone. The general outline for cloning a cDNA coding for a given protein, starting from eucaryotic messenger RNA has been described by Ullrich, A., supra, and Seeburg, P.H., et al, supra. Briefly recapitulated herein, the procedure includes the following steps: 1) isolation of polyadenulated RNA, substantially undegraded, from the differentiated cells or tissue that produce the desired pratein, 2) synthesis of a DNA strand complementary in base sequence to the isolated RNA, using reverse transcriptase and yielding an RNA-DNA hybrid, 3) selective degradation of the RNA portion of the hybrid, leaving a single-stranded cDNA, 4) synthesis of DNA complementary to the single-stranded cDNA, to form double-stranded cDNA, 5) fractionation of the double-stranded cDNA, to enrich the preparation for molecules in the desired size range, 6) preparation of a selected transfer vector to permit insertion of the cDNA, 7) covalent joining of the cDNA with the transfer vector, using DNA ligase, to yield a recombinant transfer vector, and 8) replication of the desired recombinant transfer vector by transformation, selection and growth of a suitable host microorganism strain. Anterior pituitary cells may be obtained either from human pituitary gland-s removed by transphenoidal hypophysectomy or from certain human pituitary tumor cell lines grown in culture RNA isolated from either source is partially purified to enhance the ultimate yield and used as a template for transcription into cDNA. Partial purification may include sedimentation in a sucrose gradient to remove RNA that is either too small or too large. Additional purification by chromatography on oligo-dT cellulose may be employed to isolate polyadenylated RNA, which is the principal form of messenger RNA in eucaryotic cells. Partially purified messenger RNA may be used as a template to construct cDNA using the enzyme, reverse transcriptase. The formation of double-stranded cDNA, using reverse transcriptase in combination with S1 nuclease and certain separation techniques, has been previously described. (See, Ullr ch, A. et al., Science 196, 1313 (1977) and Seeburg, P.H. et al., Nature 270, 486 (1977) ). The resulting cDNA product is heterodisperse in length. If the nucleotide sequence of the cDNA to be cloned were known or predictable within reasonable probability limits, and if restriction sites could be located reasonably close to the beginning and end of the gene to be cloned, suitable restriction enzymes could be used to render the desired cDNA product homogeneous in length and separable from contaminants of differing sequences. It will be understood that such nucleotide sequence information is unavailable for'genes, such as human pre-growth hormone, which have never previously been isolated and purified, except possibly under certain exceptional and fortuitous circumstances. Consequently, all subsequent steps generally must be carried out with the heterogeneous cDNA product. Sufficient information regarding part of the nucleotide sequence of human growth hormone cDNA was available from previous data disclosed in application Serial No. 897,710 by Goodman, et al., to make possible the identification of subfragments of the pre-growth hormone gene, as described, supra. From the known number of amino acids in human pregrowth hormone, the approximate length of the desired cDNA was estimated to be 800 base pairs. Double-stranded cDNA whose gel-electrophoresis mobility corresponded to about 800 base pairs was found, upon cleavage with the restriction enzymes PvuII and Bg1II, to contain predominantly growth hormone coding sequences. The transfer of cDNA to a DNA transfer vector could be accomplished at any random site on the vector generated by a single endonuclease hit coupled with attachment of the cDNA by DNA ligase-catalyzed blunt-end ligation. (Sgaramella, V. et al., Proc. Nat. Acad. Sci USA 67,1468 (1970)). However, selection is greatly simplified and yields are enhanced by using a specific insertion site whose location in the transfer vector is known, and by treating the cDNA to enhance the insertion specificity. In a preferred embodiment, a plasmid transfer vector having a single restriction site located with a marker gene is used. The circular plasmid DNA is cut with the appropriate restriction endonuclease. Joining the ends of the cDNA to the ends of the open plasmid DNA results in formation of a circular, recombinant plasmid, with the cDNA inserted at the restriction site, effectively interrupting the marker gene, thereby causing loss of the marker gene function. For example, plasmid pBR322 contains a single HindIII restriction site, located with the promoter for the gene for tetracycline resistance. E. coli cells transformed by pBR322 are rendered able to grow and divide in the presence of as much as 20 pg/ml tetracycline in the growth medium. In contrast, under the same condition, untransformed cells are killed. Cells transformed by a recombinant pBR322 containing an insertion at the HindIII site are unable to grow and divide in the presence of 20 pg/ml tetracycline. The plasmid pBR322 also carries a gene conferring ampicillin resistance. These genetic markers in combination permit selection of transformed cells from untransformed cells by growth of only the former in the presence of ampicillin, and selection of those transformed by non-recombinant pBR322 from recombinant pBR322 by growth of only the former in the presence of tetracycline. Insertion specifity and yield in HindIII-cut pBR322 is enhanced by attachment of HindIII-linker oligonucleotides to the ends of the heterogeneous cDNA. See Scheller, R.H. et al., supra. Further side reaction in formation of the recombinant transfer vector, such as ring closure without insertion of the cDNA, or dimerization, are substantially reduced by pretreating the ends of restriction-cut transfer vector DNA to remove the 5' terminal phosphate groups, as described by Shine in co-pending application Serial No. 898,887. Used in combination, the foregoing techniques substantially increase the absolute and relative yields of the desired recombinant transfer vectors. In previous cloning studies, the cDNA was synthesized from messenger RNA derived from pooled cell extracts of several individuals. The present invention provides techniques for obtaining a cloned gene derived from a single individual. The technique combines reductions in scale and reaction volume, assays that do not consume the product, and elimination of carrier DNA. The latter feature surprisingly improves over-all yield and efficiency of the various enzyme-catalyzed reactions used in the process. Messenger RNA is isolated from individual pituitary tumors by appropriately scaled published procedures (Seeburg, et al., supra). Column chromatography steps may be conducted in small glass tubes with a drawn tip, for example in Pasteur pipettes. Purifications to remove protein may be carried out by any of several suitable phase separation techniques such as phenol extraction, preferably by extraction with chloroform-saturated phenol. Concentration of nucleic acids by precipitation with alcohol at low temperature may be employed throughout, preferably by ethanol precipitation at -70 C. Both the extraction procedure and the precipitation procedure may be accomplished in a single tube, prefably a conical plastic centrifuge tube of Iml 2ml total volume. Enzyme reactions, such as treatment with reverse transcriptase, may also. be carried out in the same small reaction tubes. Typically, the rate and extent of synthesis of single-stranded and double-stranded cDNA is followed by incorporation of a radioisotope label in the nascent cDNA. A convenient label is L 32P]incorporated at the alpha position of one of the nucleoside triphosphate precursors, for example a-32P-dCTP. Use of radioactive labeling also permits subsequent monitoring of the cDNA product during passage through columns and on electrophoresis gels. Where it is necessary to monitor a series of column chromabography fractions, for example after chromatography to remove unreacted precursors in the reverse transcriptase reaction, a radioassay which does not consume the reaction product is highly desirable. In the present method, fractions collected in the small plastic tubes described, supra, are tightly capped. The tubes are then placed directly into scintillation vials without scintillation fluid. The resulting Cerenkov radiation may be counted with reasonable efficiency with appropriate instrument settings. Procedures involving small amounts of DNA have typically been performed with carrier DNA added to the mixture. The rationale for using carrier DNA is to improve the recovery of the desired DNA, which might otherwise be low due to nonspecific adsorption to container walls, or to lack of whatever cooperative effects operate in DNA precipitations and the like. Suitable yieLds of DNA are obtained in the absence of added carrier DNA, even with the nanogram quantities of DNA available. Omission of carrier DNA poses two distinct advantages in the present method; first, there is no non-specific DNA to yield non-specific reaction products in the enzyme-catalyzed reactions; second, there is no contaminating DNA to yield non-specific recombinant transfer vectors. By the use of the described techniques in combination, it is possible to clone the deoxynucleotide sequence coding for human pre-growth hormone from the pituitary gland of an individual human patient. In the following examples, the isolation and purification processes are described in detail and proof of the identity of the cloned gene is given by nucleotide sequence analysis. EXAMPLE 1 Process of cloning a gene coding for human pre-growth hormone from the tissue of a single individual. The pituitary glands of six human patients with pituitary tumors were removed by transphenoidal hypophysectomy, quick-frozen and stored in liquid nitrogen. In the following procedure, each pituitary gland was treated separately, although all 6 were worked up at the same time. The glands were thawed and homogenized in 4 M guanidinium thiocyanate containing 1 ti mercaptoethanol buffered to pH 5.0 at 40C. Each homogenate was layered over 1.2 ml 5.7 M CsC1 containing 1OmM EDTA and centrifuged for 18 hours at 37,000 rpm in the SW 50.1 rotor of a Beckman ultracentrifuge at 150C (Beckman Instrument Co., Fullerton, California). RNA traveled to the bottom of the tube. Further purification of the messenger RNA, using an oligo-dT cellulose column was performed essentially as described by Ullrich, A. et al., supra, and Seeburg,P-H. et al., supra. The biologicai activity of the partially purified messenger RNA was measured by its ability to direct the incorporation of [35S]-methionine into growth hormone in a cell-free protein synthesis system derived from wheat germ. The experimental conditions for the test were essentially as described by Martial, 2.H. et al., Proc. Nat. Acad. Sci. USA 74, 1816 (1977). Figure 1 shows the results of one such test. - The radioactive protein products were fractionkbd by gel electrophoresis on a 12.5goo polyacrylamide gel containing 0 sodium dodecylsulfate for 4 hours at 20 mA. The radioactive protein bands were detected by autoradiography. Band (a) shows r14C-labeled marker proteins from bacteriophage T4 used as size markers. Bands 1-6 show the translation products of the oligo-dT cellulose-purified messenger RNA from the individual tumors. It can be seen with tumors 1-5 that pregrowth hormone constitutes the major cell-free synthetic product. The RNA preparations most enriched in pre-growth hormone cell-free translational activity (samples producing bands 2, 4 and 5) were pooled and wereçused as template for the synthesis of double-stranded cDNA. AiX.reaction steps were carried out in 1.5 ml. capacity plastic centrifuge tubes. The first reverse transcriptase-catalyzed reaction, resulting in an RNA-DNA hybrid, was carried out in a reaction mixture containing 68 pl of the RNA preparation containing approximately 13 ijg RNA, avian myeloblastosis virus reverse transcriptase, 4 pl of undiluted preparation as obtained from the Office of Program Resources and Logistics, Viral Cancer Program, Viral Oncology, Division of Cancer Cause and Prevention, National Cancer Institute, Bethesda, Maryland, and 32 pl of a reaction mixture comprising 10 yl- "reverse transcriptase buffer" (0.5 M Tris-HC1 pH 8.3, 1 mM EDTA, 70 mM MgC12, 200 mM KC1), 1 pl 2-mercaptoethanol 1 M, 5 pl oligo-dT1ug/ml, 5 p1 each of dATP, dCTP and TTP (20 mM stock solutions), 1 pl dCTP 20 mM stock solution, and approximately 2x106 cpm &alpha;-[ êP]- dCTP dissolved directly in the reaction mixture. The reaction was carried out under conditions essentially as described by Seeburg, P.H. et al.; supra. The incubation mixture was extracted with chloroform-saturated phenol in the same reaction tube, then precipitated with ethanol, the tubes stored at -700C for at least 15 minutes, then centrifuged. The precipitated RNA-DNA hybrid was dissolved in 0.1 N NaOH, 5 mM EDTA, 125 pl, and incubated at 680C. for 1/2 hour to permit selective alkaline hydrolysis of RNA. The reaction mixture was loaded on a small column of Sephadex G-50 in a Pasteur pipette and eluted with buffer containing 10 mM Tris (pH 7.5) and 0.5 mM EDTA. (Sephadex G-50 is a Trade Mark of Pharmacia Inc., Piscataway, New Jersey.) The radioactive single-stranded DNA was recovered in a single 2-drop fraction collected in an Eppendorf tube. The fraction tubes were capped, placed in scintillation vials and counted in a liquid scintillation counter set for detection of Cerenkov radiation. The synthesis of the double-stranded cDNA from the single-stranded cDNA product of the previous reaction steps was carried out by a reverse-transcriptase catalyzed reaction. The reaction was carried out in a total volume of 51 pl- containing 30 pi of the single-stranded DNA solution, 3.5 pl of the enzyme solution, and 17.5 pi of a reaction mixture composed as follow-s: water, 96 iii; reverse-transcriptase buffer, 60 'Li; 2-mercaptoethanol 1 M, 6 pi, dATP 20 mM, 15 p dGTP 20 mM, 15 pi; TTP 20 mM, 15 pi; dCTP 20 mM, 3 pi; &alpha; ;-[ êp] dCTP, approximately 6x108 cpm, dissolved directly in the reaction mixture. The reaction was allowed to proceed for 90 minutes at 470C. The reaction was terminated and protein removed by the extraction and Sephadex G-50 chromatography steps described, supra, followed by ethanol precipitation as described. To confirm the fact that cDNA coding for growth hormone was an abundant species in the preparation, a portion of the double-stranded cDNA preparation was cleaved with restriction endonucleases and analyzed by polyacrylamide (4.5) gel electrophoresis (Figure 2). Lanes (c) and (k) of Figure 2 show the bands from radiolabeled bacteriophage fd DNA cleaved by endonucleases -HpaII, lane (c), and HaeIII, lane (k). Lanes (a) and (b) show the uncleaved doublestranded cDNA. Lanes (d) through (j) show the DNA cleaved by: lane (d) PstI plus BglII; lane (e) PvuII; lane (f) PvuII plus Bg1II; lane (g) Hinf plus SmaI; lane (h) HaeIII; lane (i) PvuII. and lane (j) HaeIII. The pattern of bands observed was that expected from cDNA complementary to human growth hormone mRNA as based on the structure of a previouslycloned 550 base-pair fragment of human growth hormone, described in application Serial No. 897,710, incorporated herein by reference. These data confirmed the fact that the predominant cDNA was indeed complementary to human growth hormone messenger RNA. The resulting double-stranded cDNA was treated with S1 nuclease essentially as described by Ullrich, A. et al., supra, to cleave the t'hairpi-n" structure in the unpaired loop region. The enzyme treatment was followed, as in previous steps, by extraction, chromatography and precipitation. Any unpaired ends were completed with a DNA polymerase I-catalyzed reaction. The reaction mixture, 20 pl total volume, contained 60 mM Tris-HC1, pH 7.5, 8 mM Mg-C12, 10 mM 2-mercaptoethanol, 1 mM ATP, 200 sM each of dATP, dTTP, dGTP and dCTP. The mixture was incubated with 1 unit of E. coli DNA polymerase I (Boehrin-ger-Mannheim Biochemicals, Indianapolis, Indiana) at- 100C for 10 minutes to exonucleolytically remove any 3'-protruding ends and to fill any 5'-protruding ends with complementary sequences. The reaction was designed to yield a population of cDNA molecules with blunt ends. Linker oligonucleotides specific for the HindIII restriction site sequence were added to the cDNA ends by blunt end ligation, using DNA ligase, as described by Seeburg7 P.H. et al, supra. Plasmid pBR322, Bolivar, F. et al., Gene 2, 95 (1977) was chosen as transfer vector, for reasons described, supra. The insertion and screening techniques have been described by Ullrich, A. et al., supra. Ampicillin resistant colonies were picked and transferred to plates containing ampicillin and tetracycline. Those colonies found to be ampicillin-resistant bsst tetracycline-sensitive were chosen for further study. Defective insertions, including deletions-and duplications, were detected by slab gel electrophoreis runs of HindIII-treated plasmid DNA isolated from cultures grown up from single colonies of transformed cells, selected as described. Such defects were readily detectable by the sizes of the HindIII fragments. The cloned DNA was identified as coding for human pregrowth hormone, after being released from the transfer vectorby HindIII digestion, by further treatment with restriction enzymes PvuII and B91II. The released cDNA and restriction fragments were fractionated by gel electrophoresis, in which the DNA was detected by fluorescence staining with ethidium bromide. The results are shown in Figure 3,oriented such that larger DNA fragments are located nearer the top of the figure. Lane (a) is a previously cloned 550 base-pair fragment of human growth hormone DNA, described in application Serial No. 897,710. Lane (b) is the 800 base-pair human pregrowth hormone DNA of the present example. Lanes (c) and (e) are samples of the 500 base-pair fragment cleaved with PvuII and Bg1II, respectively. Lanes (d) and (f) are samples of the 800 base-pair pre-growth hormone DNA cleaved by PvuII and Bg1II, respectively-. Cleavage by PvuII yields fragments of similar size in both cases, as expected from the known location of a PvuII site near an end of the 500 base-pair fragment. Cleavage of Bg1II yields larger fragments with the 800 base-pair DNA than with the 550 base-pair fragment, as expected. These findings are consistent with the identifi cation of the cloned 800 base-pair fragment as containing human growth hormone gene sequences. The cloned DNA, designated cHGH800 was chosen for sequence analysis. EXAMPLE 2 Nucleotide sequence analysis of 'cHGH8O0. The nucleotide sequence of cHGH800 was determined by the method of Maxam and Gilbert, Proc. Nat. Aces. Sci. USA 74, 560 (1977) and by the method of Sanger, F. et al., Proc. Nat. Acad. Sci. USA 74, 5463 (1977). The result is shown in Table 4. The cloned gene includes the entire sequence coding for human pre-growth hormone, together with a 29 base-pair region at the 5'-end, presumably untranslated, as well as an untranslated region of 108 base pairs at the 3'end (excluding the poly-A portion). (The 5'- and 3'- ends are designated by reference to that strand of the cDNA corresponding in sequence to the growth hormone messenger RNA). Some uncertainty remains in the pre-sequence near the beginning of the growth hormone sequence. It is also noted that the nucleotide sequence of Table 4 yields an amino acid sequence for growth hormone which differs slightly from the published sequence. The amino acid sequence inferred from nucleotide sequence analysis is considered to be more likely the correct one. The disagreements occur in distinguishing amino acid pairs such as Gln or Glu, which are less readily distinguishable by direct amino acid sequencing than by nucleotide sequencing. Further, nucleotide sequence analysis provides information previously unobtainable, for example, the probable amino acid sequence of the growth hormone presequence. TABLE 4 A. B continues on page 26 Translation of cHGH80@ -26 met ala thr gly ser arg GG A:C CUG UGG ACA GCU CAC CUA GCU CCA AUG CCU ACA GGC UCC CGG 1 10 leu gln glu ala val pro phe pro thr ile pro leu ser arg leu phe CUU CAA GAG GCA GUG CCU UUC CCA ACC AUU CCC UUA UCC AGG CUU UUU 30 40 phe asp thr tyr gln glu phe glu glu ala tyr ile pro lys glu gln UUU GAC ACC UAC CAG GAG UUU GAA GAA GCC UAU AUC CCA AAG GAA CAG 60 70 ser glu ser ile pro thr pro ser asn arg glu glu thr gln gln lys UCA GAG UCU AUU CCG ACA CCC UCC AAC AGG GAG CAA ACA CAA CAC AAA 90 100 ser trp leu glu pro val gln phe ieu arg ser val phe ala asn ser UCG UGG CUG GAG CCC GUG CAG UUC CUC AGG AGU GUC UUC GCC AAC AGC 120 130 lys asp leu glu glu gly ile gln tr leu met gly arg le.u glu asp AAG GAC CUA GAG GAA GGC AUC CAA ACG CUG AUG GGC AGG CUG GAA CAU 150 160 lys phe asp thr asn ser his asn asp asp ala Ieu lcu lys asn tyr AAG UUC GAC ACA AAC UCA CAC AAC GAU GAC GCA CUA CUC AAG AAC UAC 180 190 thr phe leu arg ile val gln cys arg ser val glu gly ser cys gly ACA UUC CUG CGC AUC GUG CAG UGC CCC UCU GUG GAG CCC AGC UGU CCC CUC UCC UGG CCC UGG -AAG UUG CCA CUC CAG UGC CCA CCA GCC UUG UCC TABLE 4 B. continued from page 25 -20 -10 thr ser leu leu lou ala phe gly leu leu cys leu pro trp ACG UCC CUG CUC CUG GCU UUU GGC CUG CUC UGC CUG CCC UGG 20 asp asn ala met leu arg ala his arg leu his gln leu ala GAC AAC GCU AUG CUC CGC GCC CAU CGU CUG CAC CAG CUG GCC 50 lys tyr ser phe leu gln asn pro gln thr ser leu cys phe AAG UAU UCA UUC CUG CAG AAC CCC CAG ACC UCC CUC UGU UUC 80 ser asn leu glu leu leu arg ile ser'leu leu leu ile gin UCC AAC CUA GAG CUG CUC GC AUC UCC CUG CUG CUC AUC CAG llf3 leu val tyr gly ala ser asp ser asn val tyr asp leu leu CUG GUG UAC GGC GCC UCU GAC AGC AAC GUC UAU GAC CUC CUA 140 gly ser pro arg thr gly, gln- ile phe lys gln thr tyr ser GGC AGC CCC CGG ACU GGG CAG AUC UUC AAG CAG ACC UAC AGC its gly leu leu tyr cys phe arg lys asp met asp lys val glu GGG CUG CUC UAC UGC UUC AGO AAG GAC AUG GAC AAG GUC GAG 191 phe AM UUC UAG CUG CCC oca UCG CAU CCU GUG ACC CCU CCC CAG UGC UAA UAA AAU UAA GUU GCA UCA AAA AAA AAA EXAMPLE 3 Construction. of plasmid ptrpEDSO-HGH. A plasmid designated ptrpED5-1, (obtained from Searle Research Laboratories, High Wycombe, Bucks, England), was modified to permit insertion and expression of the cloned pre-growth hormone cDNA. Plasmid ptrpED5-1 was derived from the HindIII fragment of the E. coli tryptophan (trp) operon, transferred from bacteriophage AtrpE, as described by Hopkins, A.S. et al., J. Mol. Biol. 107, 549 (1976.), inserted in the HindIII site of pBR322, Bolivar, F. et al, Gene 2, 95 (1977). Plasmid ptrpED5-1. was cleaved with HindIII, and treated with the Kenow fragment of DNA - polymerase I to pair the single-stranded. 5'-ends (Seeburg, P.H. et al., supra). Decanueleotide Hind III linkers were attached to the plasmid DNA. Cohesive ends were then generated by HindlIl and the plasmid DNA was isolated by Sephadex G100 chromatography. (Sephadex G-100 is a Trade Mark of Pharmacia Inc., Uppsala; Sweden). The circular plasmid was regenerated with the use of T4-DNA ligase, and used to transform the RR-I strain of r. coli. Plasmid p m ED50 containing clones were isolated by selection for zampicillin resistance. Cloned human pre-growth hormone DNA (cHGH8O0 as described in Examples 1 and 2) was inserted at the HindIII site of ptr.pED50. The recombinant transfer vector was used to transform E. coli XI 776. Transformants were selected on ampicillin-containing plates. Plasmid DNA isolated from several clones was tested for correct orientation of insertion by cleavage with BamHI and PstI. Correct orientation, such that codons of pre-growth hormone would be read in phase with those of the trp operon, was inferred from the asymmetric location of the PstI site, yielding a 700 base-pair fragment. Incorrect orientation would yield a 290 base pair fragment. Plasmids with correct orientation, designated ptrpED50-HGH, were then transformed into E. coli trpOEv1. EXAMPLE 4 Expression of human pre-growth hormone. In plasmid pED5O-HGH, expression of the trpE and trpD genes is under tryptophan control, such that the levels of protein products coded by these genes is elevated from a basal level by the presence of an inducer such as ss-indolylacrylic acid. Induction of E. coli trpOEv1/ptrp- ED5O-HGH is expected to result in increased production of the trpE gene product and of a trpD-pre-growth hormone fusion protein. The latter comprises part of the NH2terminal portion, the trpD gene product joined to human pregrowth hormone. A culture of E. coli trp0Evl /ptrpEDSO-HGH was induced with 8-indolylacrylic acid, and 3 ml samples were pulse labeled with 2 pCi of 14C-labeled amino acids for a constant time, at various intervals after induction. Samples from the zero and 4 hour induced cultures were immunoprecipitated using formaldehyde-tieated Staphyloccocus aureus to collect antigen-antibody complexes as described by Martial, J.A. et al., Proc. Nat. Acad. Sci. USA 74 1816 (1977). The proteins were solubilized and fractionated by electrophoresis in sodium dodecylsulfate-polyacrylamide gels. Results are shown in Figure 4. Lane (a) contains 14C-labeled proteins from bacteriophage T4-infected E. coli cells, used as size markers. Tracks (b) through (g) show pulse-labeled proteins at 0, 0.5, 1, 2, 3 and 4 hour-s, respectively, after induction. Track (h) shows the immunoprecipitated proteins from 4 hour induced cultures, with antisçwum against human growth hormone. Track (i) shows the immunoprecipitate of the 4 hour induced pulse-labeled proteins with non-immune serum. Track (j) shows the immunoprecipitate of pulse-labeled, uninduced proteins. The upper and lower arrows show, respectively, the locations of the trpE and expected trpD-HGH fusion proteins. Numbers on the left indicate molecular weights X10 of the marker proteins. The results show the appearance of the trpD-HGH protein following induction and its specific precipitation by anti human growth hormone serum. There is also a certain amount of immunoprecipitated trpE protein. Since the trpE and trpD proteins are normally associated in a complex, it seems likely that some association occurs between the trpE protein and the trpD-HGH fusion protein, by virtue of the trpD portion of the fusion protein. In any case, the evidence demonstrates the expression of the cloned human pre-growth hormone gene in E. coli. While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth, and as follows in the scope of the appended claims.

Claims: CLAIMS. 1. A DNA transfer vector comprising a deoxynucleotide sequence coding for human pre-growth hormone. 2. The transfer vector of claim 1 where the deoxynucleotide sequence coding for human pre-growth hormone is derived from messenger RNA isolated from the pituitary gland cells of an individual human. 3. A microorganism transformed by the transfer vector of claim 1. 4. A DNA transfer vector comprising a deoxynucleotide sequence coding for human pre-growth hormone comprising: 5'-GGATCCTGTGGACAGCTCACCTAGCTGCAATG26 CCL -25 ACL 24GGL 23 QR-22S-22W-21GZ-21ACL¯20QR-19s-19x-18TY-18X-17TX-17X-16 Ty-16GCL-15TTK-14GGL-13X-12TY-12X-11TY-11TGK-10XTY -12 X11 TY -11 TCK -10 X9 TV -9 CCL-8TGG-7X-6CAJ-5GAJ-4GCL-3GTL-2CCL-1TTK1CCL2ACL3ATM4 CCL5X6TY6R7S7W8GZ8X9 TY9TTK10GAK11AAK12GCL13ATG14X15TY15 W16CZ16GCL17CAK 18W19CZ19X20TY20CAK21CAJ22X23TY23GCL24TTK25 GAK26ACL27TAK28CAJ29GAJ30TTK31GAJ32GAJ33ACL34TAK35ATM36CCL37 AAJ38GAJ39CAJ40AAJ41TAK42QR43S43TTK44X45TY45CAJ46AAK47CCL48 CAJ49ACL50QR5 S51 X52TV52TCK53TTK54R55S55GAJ56R57S57ATM58 CCL59ACL60CCL61QRS62AAK63W64GZ64GAJ65GAJ66ACL67CAJ68CAJ69 AAJ70QR71AAK72X73TY73GAJ74X75TY75X76TY76W77GZ77ATM78QR79 S79X80TY80X81 TY81 X82TY82ATM83CAJ84QR85S85TGGX87 TY87GAJ88 CCL89GTL90CAJ91TTK92X93TY93W94GZ94QR95S95GTL96TTK97GCL98 AAK99AAK100X101 TY101 GTL102TAK103GGL104GCL104GCL105QR106S106GAK107QR108 S108AAK109GTL110TAK111GAK112X113TY113X114TY114AAJ115GAK116X117 TY117GAJ118GAJ119GGL120ATM121CAJ122ACL123X124TY124ATGGCL126 W127GZ127X128TV128GAJ129GAK130CGL131R132S132CCL133W134CZ134 ACL135GGL136CAJ137ATM138TTK139AAJ140CAJ141 ACL142TAK143QR144 S144AAJ145TTK146GAK147ACL148AAK149QR150S150CAK151 AAK152CAK153 54 155 156 156 157TY157AAJ1sgAAK159TAK16oGGL TAX 160GGL161X162 TY162X163TY163TAK164GK165TTK166W167GZ167AAJ168GAK169ATGGAK171 AAJ172GTL173CAJ174ACL175TTK176X 177TV177 W 178CZ178ATM 179GTL180 CAJ181TGK182W183GZ183QR184S184GTL185GAJ186GGL187QR188S188 TGK189GGL190TTK191TAGCTGCCCGGGTGGCATCCCTGTGACCCCTCCCCAGTGCCT CTCCTGGCCCTGGAAGTTGCCACTCCAGTGCCCACCAGCCTTGTCCTAATAAAATTAAGT TGCATCpolyA - 3' wherein A is deoxyadenyl, G is deoxyguanyl, C is deoxycytosyl, T is thymidyl, J is A or G; K is T or C; L is A, TC or G; M is A, C or T; X is T or C, if Y is A or G, and C if Y is C or T; n n n V is A, G, C, or T, if X is C, and A or G if X is T; n n n W is C or A, if Z is G or A, and C if Z is C or T; n n n Z is A, G, C or T, if Wn is C, and A or G if W is A; n n QRn is TC, if 5n is A, G, C or T, and AE if 5n is T or C; ; S is A, C, C or T, if ORn is TC, and T or C if QRn is n AG and subscript numerals, n, reFer to the position in the amino acid sequence of human growth hormone, to which each triplet in the nucleotide sequence corresponds, according to the genetic code, the amino acid positions being numbered from the amino end. 5. A microorganism transformed by the transfer vector of claim 4. 6. The plasmid pBR322/HGH800. 7. A microorganism transformed by the plasmid of claim 6. 8. The plasmid ptrpED5C-HGH. 9. A micrçrganism transformed by the plasmid of claim 8. 10. A microorganism as in claim 9 comprising Escherichia coli. 11. A chimeric protein comprising the amino acid sequence of human pre-growth hormone as its C-terminal sequence, and a portion of a procaryotic protein as its N-terminal sequence. 12. The protein of claim 11 wherein the procaryotic portion is coded by part of the trpD gene of Escherichia coli. 13. A method for cloning a deoxynucleotide sequence coding for human pre-growth hormone from pituitary gland tissue of an individual human, comprising the steps of a) extracting mRNA coding for human pre-growth hormone from an individual human pituitary gland, b) separating the mRNA substantially free of protein, DNA and other RNA, c) synthesizing a single-stranded cDNA having a nucleotide sequence complementary to that of the mRNA, in a series of procedures including incubation with an enzyme, extraction to remove protein from the reaction mixture, alcohol precipitation, and alkaline hydrolysis, all of said procedures being carried out in the same reaction tube, in the absence of added carrier DNA, d) purifying the single-stranded cDNA by chromatography wherein those fractions containing the single-stranded DNA are located by a radioassay which does not consume the inaction product, 2) synthesizing double-stranded cDNA having one strand with a nucleotide sequence corresponding to that of the mRNA, in a series of procedures including incubation with an enzyme, and extraction to remove prptein, said procedures being carried out in a single reaction tube in the absence of added carrier DNA, f) purifying the double-stranded cDNA by chromatography as in step d), g) further treating the double-stranded cDNA with enzyme, essentially as described in steps e) and f) to provide end groups suitable for inserting the cDNA into a DNA transfer vector, h) inserting the double-stranded cDNA into a DNA transfer vector, thereby forming a recombinant transfer vector, i) transforming a microorganism with the recombinant transfer vector, and j) selecting a microorgamism strain derived from 9 single transformed cell transformed by a recombinant transfer vector containing cDNA coding for human pre-growth hormone, thereby cloning a deoxynucleotide sequence coding for human pre-growth hormone.

Inventors: BAXTER, JOHN DARLING, GOODMAN, HOWARD MICHAEL, HALLEWELL, ROBERT ALEXANDER, MARTIAL, JOSEPH AUGUSTIN
Applicants: THE REGENTS OF THE  UNIVERSITY OF CALIFORNIA
Application year: 1980
Main classification: C12N15
IPC codes: C12N1, C07K14, C07K19, C12N15, C12P21, C07H21, C12R1, C12P19